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Abstract
Background: Extensive genetic diversity in vaccine antigens may contribute to the lack of efficacy of blood stage 
malaria vaccines. Apical membrane antigen-1 (AMA1) is a leading blood stage malaria vaccine candidate with extreme 
diversity, potentially limiting its efficacy against infection and disease caused by Plasmodium falciparum parasites with 
diverse forms of AMA1.
Methods: Three hundred Malian children participated in a Phase 2 clinical trial of a bivalent malaria vaccine that found 
no protective efficacy. The vaccine consists of recombinant AMA1 based on the 3D7 and FVO strains of P. falciparum 
adjuvanted with aluminum hydroxide (AMA1-C1). The gene encoding AMA1 was sequenced from P. falciparum 
infections experienced before and after immunization with the study vaccine or a control vaccine. Sequences of ama1 
from infections in the malaria vaccine and control groups were compared with regard to similarity to the vaccine 
antigens using several measures of genetic diversity. Time to infection with parasites carrying AMA1 haplotypes similar 
to the vaccine strains with respect to immunologically important polymorphisms and the risk of infection with vaccine 
strain haplotypes were compared.
Results: Based on 62 polymorphic AMA1 residues, 186 unique ama1 haplotypes were identified among 315 ama1 
sequences that were included in the analysis. Eight infections had ama1 sequences identical to 3D7 while none were 
identical to FVO. Several measures of genetic diversity showed that ama1 sequences in the malaria vaccine and control 
groups were comparable both at baseline and during follow up period. Pre- and post-immunization ama1 sequences 
in both groups all had a similar degree of genetic distance from FVO and 3D7 ama1. No differences were found in the 
time of first clinical episode or risk of infection with an AMA1 haplotype similar to 3D7 or FVO with respect to a limited 
set of immunologically important polymorphisms found in the cluster 1 loop of domain I of AMA1.
Conclusion: This Phase 2 trial of a bivalent AMA1 malaria vaccine found no evidence of vaccine selection or strain-
specific efficacy, suggesting that the extreme genetic diversity of AMA1 did not account for failure of the vaccine to 
provide protection.
Background
Combined with other measures, vaccination is consid-
ered a promising approach to control and eventually
eliminate malaria [1,2]. Extensive polymorphism in many
Plasmodium falciparum proteins may limit the efficacy of
vaccines based on just one or two allelic variants that are
not broadly cross-protective against diverse antigens
found in natural infections. For example, a multi-antigen
blood stage malaria vaccine evaluated in Papua New
Guinea reduced parasite density and prevalence of infec-
tion in a strain-specific manner, suggesting selection of
non-vaccine variants [3]. In contrast, immunization with
RTS,S, a vaccine directed against the pre-erythrocytic
circumsporozoite protein [4], does not appear to result in
selection or allele-specific efficacy [5,6].
Apical membrane antigen-1 (AMA1) is a leading blood
stage malaria vaccine candidate that is thought to play a
critical role in erythrocyte invasion. Antibodies against
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AMA1 have been shown to block parasite invasion [7-
11], and sero-epidemiological studies have shown an
association of anti-AMA1 antibodies with naturally
acquired protection against malaria [12,13]. Animal stud-
ies [14] have shown the ability of vaccines based on this
antigen to stimulate antibody responses that were corre-
lated with a reduction of parasite density.
AMA1 is expressed mainly during the P. falciparum
asexual or blood stage, and examination of ama1
sequences from natural P. falciparum infections has
shown extreme diversity in this gene. There are up to 62
polymorphic amino acid sites in AMA1, representing
more than 15% of the amino acid sites distributed over
three domains of the protein [15,16]. The greatest poly-
morphism is seen in domain I, especially in a cluster of
amino acids near a hydrophobic pocket [17] that is
thought to play a role in erythrocyte invasion, the cluster
1 loop of domain I (c1L), which includes amino acid resi-
dues 196, 197, 199, 200, 201, 204, 206 and 207 [18]. Based
on antigenic escape modeling, growth and invasion inhi-
bition assays [19] and molecular epidemiological studies
of the impact of AMA1 polymorphism on risk of clinical
malaria [16], c1L has been identified as a key target of
both strain-specific antibodies and allele-specific natu-
rally acquired protective immune responses.
The malaria vaccine AMA1-C1 is a bivalent vaccine
comprised of recombinant AMA1 based on the 3D7 and
FVO reference strains of P. falciparum expressed in
Pichia pastoris and adjuvanted with aluminum hydrox-
ide, developed by the Malaria Vaccine Development
Branch of the National Institute for Allergy and Infec-
tious Diseases of the U.S. National Institutes of Health
and tested at the Malaria Research and Training Center at
the University of Bamako in Mali. Phase 1 studies of
AMA1-C1 in Malian adults and children showed that it
was acceptably safe and tolerable and modestly immuno-
genic [20,21]. However, as with other vaccine antigens,
the high degree of polymorphism observed in this protein
[16,22-24] and possible strain specificity of the immune
response [25] may limit its success as a vaccine candidate.
Since failures of AMA1 vaccine in animal models have
been attributed to the diversity of the antigen used in vac-
cine formulation [26,27], careful measurement of allele-
specific efficacy and vaccine selection are important
components in assessing the efficacy of malaria vaccine
candidates in field trials conducted in endemic countries
[28].
A Phase 2 clinical trial of AMA1-C1 vaccine in Malian
children showed no impact of vaccination on parasite
density or clinical malaria [29]. Even in the absence of
measurable overall parasitological or clinical efficacy, it
was hypothesized that children who received the AMA1
vaccine might have a decreased incidence of clinical
malaria caused by parasites having AMA1 alleles similar
to the vaccine alleles as a consequence of the strain speci-
ficity of the immune response. In this scenario, the low
vaccine efficacy might be explained by the vaccine only
providing protection against parasites with AMA1 haplo-
types (based on the immunologically relevant polymor-
phic amino acid residues in c1L) similar to those of the
strains represented in the vaccine formulation.
Data and samples collected during this trial were used
to assess whether this bivalent malaria vaccine produced
a response that was specific to the vaccine antigens,
resulting in selection of alleles differing from the vaccine
strain. It was further reasoned that even if selection could
not be demonstrated directly by comparing frequencies
of vaccine-type and non-vaccine type AMA1 in vaccinees
and controls, these data might provide indirect evidence
for allele-specific immunity elicited by the vaccine.
Methods
Overall study design
Samples used in this study were collected during a dou-
ble-blind, controlled, Phase 2 trial of the safety and effi-
cacy of the AMA1-C1 malaria vaccine conducted in
Bancoumana, Mali from 2006 to 2007. The main objec-
tive of the study was to compare the protection induced
by a bivalent AMA1 vaccine composed of 3D7 and FVO
strains and a Haemophilus influenza B vaccine control
(Hiberix®, GlaxoSmithKline, Uxbridge, UK). Details on
the methods and overall results of the trial are described
elsewhere [20,29]. Briefly, 300 children aged from 2 to 3
years inclusive, were randomly assigned on a 1:1 basis to
the vaccine or control group. Two doses of vaccine were
given to patients at 28 days intervals. Immunized children
were followed for up to 52 weeks. Follow up for vaccine
efficacy started 14 days after the last immunization (day
42) and extended to Day 156. Procedures included
monthly clinical examination and malaria smears, and
blood collection on filter paper for malaria parasite typ-
ing. Those presenting with clinical symptoms outside
scheduled visits also had malaria smears and blood col-
lected on filter paper for malaria parasite typing.
Site and sample collection
Samples were collected at the Malaria Research and
Training Center research clinic in Bancoumana, a rural
village 60 km southwest of Bamako in Mali, West Africa.
The health district of Bancoumana has a population of
approximately 22,000 inhabitants. Malaria transmission
is hyper-endemic and seasonal (June-November), with
peak transmission in October. The blood collection pro-
cedure onto filter paper was performed as described by
Duan et al [30]. The study was approved by institutional
review boards of the Faculty of Medicine, Pharmacy, and
Dentistry of the University of Bamako and the National
Institute of Allergy and Infectious Diseases, and writtenOuattara et al. Malaria Journal 2010, 9:175
http://www.malariajournal.com/content/9/1/175
Page 3 of 13
informed consent was obtained from parents or guard-
ians of study participants prior to inclusion in the study.
Three hundred blood sample filter papers were collected
the day of first vaccination and served as a baseline time
point in this study. In addition, 504 infections, as deter-
mined by thick smear microscopy, were collected after
vaccination (day 42 to day 156). Finally, 291 thick smear-
negative samples from the same period of observation
were randomly selected from the study database (Figure
1) in hopes of capturing episodes of sub-patent parasitae-
mia.
DNA extraction
Malaria parasite DNA was extracted using the QiaAmp
96 DNA blood kit (Qiagen, Valencia CA) according to the
manufacturer's instructions.
Ama1 gene amplification and sequencing
A nested PCR was used to amplify the entire ectodomain
coding sequence of ama1  (1861 bp), using primers
designed by Duan et al [30]. Briefly, a nested PCR was
performed using primers F2 (tcaaattaatgtacttgtta) and R8
(ttttagcataaaagagaagc) with the following cycling condi-
tions: initial DNA denaturation at 94°C for 2 min, fol-
lowed by 38 cycles of denaturation at 94°C for 20 sec;
primer annealing at 52°C for 10 sec, and extension at 60°C
for 3 min. A final extension was conducted at 60°C for 5
min. PCR products from the first amplification were used
as the template for a second round of amplification with
primers n1 (atgagaaaattatactgcgt) and n2 (tgattatatca-
gacgttgaa). Amplification conditions were exactly the
same as in the primary amplification only with 30 cycles
instead of 38. Each primary PCR reaction contained a
total volume of 27 μl with 22.5 μl of Platinum super mix
in 96-well plates (Invitrogen, Carlsbad, CA), 1 μl of each
primer and 2.5 μl of malaria parasite DNA. The second-
ary PCR used 45 μl of Platinum Mix, 1 μl of each primer
and 5 μl of primary PCR product. PCR products were
electrophoresed on a high-throughput pre-cast gel sys-
tem (Invitrogen, Carlsbad, CA) then visualized and pho-
tographed under ultraviolet light. Amplified products
were purified using Exo-SAP-it (US Biomedical, Cleve-
land, Ohio). Purified products were sequenced using
primers described by Duan et al. [30] on an ABI 3730XL
automatic sequencer (Applied Biosystems, Foster City
CA). Sequences were deposited in GenBank [GenBank
HM562354-HM562668].
Sequence alignment, statistical and genetic analysis
DNA sequences were analysed using Sequencher 4.8 soft-
ware (Gene Codes Corporation, MI). A sequence was
considered to be from a multiple-allele infection when
the secondary peak height was 50% or more of the pri-
mary peak height at any polymorphic site. Analyses were
initially performed on the 1206 bp region covering
domain 1 to domain 3 [30] and then limited to cluster one
and one loop (c1L) as described by Dutta et al based on
antigenic escape residues [19]. Reference sequences were
the 3D7 [GenBank AF512508] and FVO strains [Gen-
Bank AF277003]. Because haplotypes could not be deter-
mined for multiple-allele infections, only sequences
classified as corresponding to single or predominant
infections with secondary peak height less than 50% of
the primary peak at polymorphic codons were used for
this analysis.
Parasite population genetic parameters were estimated
using MEGA 4.50.3 [31] and DNASP 4.50.3 [32] software.
The parameters of interest included: nucleotide diversity
(π), which is a measure of the average number of nucle-
otide differences per site between any two DNA
sequences chosen randomly from the sampled popula-
tion; haplotype diversity (Hd), measuring the probability
of randomly choosing two individuals bearing different
haplotypes; the average number of nucleotide differences
(k); the number of net nucleotide substitutions between
populations (Da); the average number of nucleotide sub-
stitutions per site (Dxy); the average number of nucleotide
differences (k); and Tajima's test, which estimates depar-
tures from neutrality by comparing an estimate of the
number of segregating sites to the average number of
mutations between pairs in the sample. Groups of
sequences were also compared by assessing changes in
allele frequencies and DNA divergence between popula-
tions. In addition, vaccine and control groups were com-
pared, before and after vaccination (Figure 2), with the
reference sequences 3D7 and FVO to assess any change
in the sequence distribution after vaccination.
AMA1 haplotypes were assigned to haplotype groups
(or subpopulations) using a Bayesian clustering algorithm
implemented in STRUCTURE software [33]. The model
conditions have been described previously [30], and con-
sisted of running ten runs of 50,000 burn-ins and 100,000
iterations were performed for K = 1 to 10 using admixture
models.
A malaria clinical episode was defined as axillary tem-
perature > 37.5°C and a parasitaemia greater than or
equal to 2,500 asexual P. falciparum parasites per mm3
[34]. SAS 9.1.3 statistical software (Cary, NC) was used to
assess the time to malaria first clinical episode with a 3D7
or FVO c1L haplotype as defined by Dutta [19] and
Takala [16]. Cox proportional hazards regression was
used to model the association between study group and
risk of a clinical episode with parasites having an AMA1
c1L haplotype identical to 3D7 or FVO. Chi square testsOuattara et al. Malaria Journal 2010, 9:175
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were used to compare the frequency of c1L haplotypes in
the two treatment arms.
Results
Measures of selection and allele-specific efficacy
Of 1,091 samples subjected to PCR amplification of
ama1, 510 were PCR-positive and 453 of these yielded
full ama1 sequences (Figure 1). Of these, 315 were classi-
fied as single/predominant allele infections and were
included in the haplotype analysis while 138 classified as
multiple-allele infections were excluded from haplotype
analyses. Table 1 shows the number of ama1 haplotypes
in each treatment group at baseline and during the effi-
cacy observation period. Among 315 ama1  sequences,
Figure 1 Flow chart showing the samples and apical membrane antigen-1 (AMA1) ectodomain sequences used in the analysis.
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186 unique amino acid haplotypes were identified with
haplotype prevalences ranging from 0.3% to 2.54% con-
firming the extreme diversity in AMA1 found at another
site in Mali [16].
Based on the entire set of polymorphic sites within the
AMA1 ectodomain (domains I, II and III), there were
eight infections with an AMA1 haplotype identical to
3D7 among the 315 analysed, all of which were detected
in samples from the post-immunization efficacy observa-
tion period; there were no 3D7-identical sequences in
infections detected among the 44 samples collected at
baseline, before immunization. No AMA1 sequences
Figure 2 Frequency of 3D7 and FVO apical membrane antigen-1 (AMA1) cluster 1 loop (c1L) haplotypes observed before and after immu-
nization in the AMA1-C1 vaccine and control groups.
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Table 1: Genetic diversity in the gene encoding apical membrane antigen-1 (AMA1) before and after immunization with a 
bivalent AMA1 malaria vaccine
Number of 
sequences
Number of 
haplotypes
Haplotype 
diversity
(Hd)
Nucleotide 
diversity
(π)
Average number of 
nucleotide differences
(k)
Tajima D Tajima D 
p-value
Control group
Baseline 23 22 0.996 0.0163 19.672 0.3308 > 0.1
Post-immunization 129 96 0.993 0.0172 20.729 1.4110 > 0.1
Control total 152 112 0.994 0.0179 20.726 0.9110 > 0.1
AMA1 vaccine group
Baseline 21 21 1.000 0.0176 21.210 0.2413 > 0.1
Post-immunization 142 94 0.989 0.0172 20.773 1.8010 > 0.05
AMA1 vaccine total 163 106 0.990 0.0172 20.792 1.0150 > 0.1Ouattara et al. Malaria Journal 2010, 9:175
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exactly matched the haplotype of the vaccine strain FVO.
Of the eight 3D7-type sequences detected during the
post-vaccination efficacy observation period, 5/142 (fre-
quency of 3.5%) were in the AMA1 malaria vaccine group
and 3/129 (frequency of 2.3%) were in the control group
with a Fisher's exact p-value of 0.72. Thus there was no
suggestion that allele-specific vaccine selection resulted
in a decreased frequency of infections harboring para-
sites with 3D7-type alleles with respect to the whole
AMA1 ectodomain.
Based only on the c1L haplotype, 14.3% sequences
matched the 3D7 vaccine strain while 4.8% matched
FVO, similar to the higher prevalence of 3D7-type AMA1
c1L at another vaccine testing site in Mali [16]. While
there was a slightly higher proportion of both 3D7 and
FVO-type AMA1 c1L haplotypes in the control group at
baseline before vaccines were administered, this differ-
ence was not significant, and there were no significant
differences in the proportions of 3D7 and FVO c1L hap-
lotypes when comparing pre-immunization to post-
immunization  P. falciparum clinical episodes (table 2)
and infections (Figure 2) in either the malaria vaccine or
control groups.
Haplotype diversity before and after immunization
To assess whether immunization with AMA1-C1
resulted in decreased ama1  diversity,  ama1  sequences
from infections present before immunization were com-
pared to those occurring after immunization. The
hypothesis was that if vaccination reduced the risk of
infection caused by parasites with AMA1 similar to the
vaccine strains, the AMA1 haplotype frequency of infect-
ing strains would be reduced, as measured by reduced
diversity parameters in the malaria vaccine group com-
pared to controls following immunization.
Immunization with the AMA1-C1 vaccine had no
effect on various measures of genetic diversity. At base-
line the two groups were comparable, with 21 haplotypes
among 21 infections in the vaccine group and 22 haplo-
types among 23 infections in the control group, and with
similar values of Hd and π in both groups (Table 1). The
average number of nucleotide differences between the
two groups at baseline was 20.805, while the average
number of nucleotide substitutions per site between the
two groups (Dxy) was 0.0172 and the net nucleotide sub-
stitutions between groups (Da) was 0.0003 (Table 3).
When comparing all post-immunization infections in the
vaccine and control groups, haplotype and nucleotide
diversity were again very similar (Table 1). Malaria vac-
cine group and control group sequences were also virtu-
ally identical with respect to the number of net nucleotide
substitutions per site after vaccination with Da value of -
0.00002. Moreover, comparing baseline sequences to
post-vaccination sequences within the malaria vaccine
and control groups, genetic diversity parameters (Hd, π,
Da and k) were also similar (Table 3). These analyses do
not provide evidence of a reduction in ama1 diversity due
to the malaria vaccine during the follow up period.
Divergence from vaccine strains
Ama1  sequences from the vaccine and control groups
were compared to the vaccine strains 3D7 and FVO to
assess whether infections experienced by individuals
receiving the malaria vaccine had sequences that were
more divergent from the vaccine strain sequences than
those in the control group. All measures of genetic differ-
entiation indicated that immunization with AMA1-C1
had no impact on genetic divergence from the vaccine
strains. Both at baseline and following immunization, the
vaccine and control group sequences were similarly
divergent from FVO and 3D7 based on K, Dxy and Da,
suggesting that the vaccine did not increase divergence
from the vaccine strains (Table 3).
Additional analyses were performed based only on the
polymorphic amino acids in cluster 1 of domain I of
AMA1 [10] which includes cluster one loop, to determine
whether evidence of selection or reduced diversity would
emerge when focusing only on those polymorphisms
thought to be most relevant to allele-specific antibody
responses [19] and to acquired clinical immunity [16].
Both at baseline and following immunization ama1 clus-
ter 1 sequences which includes conserved regions as well
Table 2: Incidence of malaria clinical episodes with apical membrane antigen-1 (AMA1) cluster 1 loop (c1L) haplotype 
matching vaccine strains
Strain and vaccine group Vaccine strain
c1L type
Non-vaccine
strain c1L type
Incidence p-value
3D7 strain
Control vaccine 12 27 30.8% 0.20
AMA1-C1 8 35 18.6%
FVO strain
Control vaccine 3 32 8.6% 0.55
AMA1-C1 3 40 7.0%Ouattara et al. Malaria Journal 2010, 9:175
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as the polymorphic positions ranging from amino acids
positions 187 to 230 were similar in the AMA1 vaccine
and control groups: At baseline, nucleotide divergence of
ama1  cluster 1 sequences compared to 3D7 cluster 1
sequence were 0.05374 and 0.0467 for the malaria vaccine
and control groups respectively. In infections occurring
after immunization, cluster 1 divergence from 3D7 was
0.066 in the AMA1 vaccine group and 0.0530 in control
group, respectively with p > 0.1, thus supporting a lack of
vaccine selection or allele-specific efficacy. A similar lack
of increased divergence from FVO in cluster 1 was
observed: nucleotide divergence was 0.0018 in AMA1
vaccine group and 0.0035 in the control group before
immunization compared to 0.0013 and 0.0022 in the
AMA1 and control group, respectively, following immu-
nization.
The similarity of c1L haplotype distribution in the two
treatment arms was further supported when the inci-
dence of infection by haplotype was compared (Table 2).
Although there was a lower incidence of clinical malaria
caused by 3D7-type AMA1 c1L in the malaria vaccine
group (18.6%) compared to the control group (30.8%) fol-
lowing immunization, this reduced frequency did not
achieve statistical significance, and there was no sugges-
tion of decreased risk of clinical malaria caused by FVO-
type AMA-1 c1L in the malaria vaccine group.
Structure analysis
Based on results from the incidence study conducted in
this site before this vaccine trial [30], we used k = 6 (Fig-
ure 3) as the number of groups in the structure analysis.
The distribution of sequences in each group is shown in
Figure 4 and was used to compute a chi-square test. The
test was not significant when the six groups of sequences
defined using clustering analysis are compared as follows:
malaria vaccine vs. control group sequences at baseline (p
= 0.81); control group sequences at baseline vs. after
immunization (p = 0.19); malaria vaccine group
sequences at baseline vs. after immunization (p = 0.67);
Table 3: Comparison of genetic divergence between apical membrane antigen-1 (AMA1) sequences P. falciparum 
infections occurring in children immunized with a bivalent AMA1 malaria vaccine or control vaccine, before and after 
immunization, and in comparison with the vaccine strains 3D7 and FVO
Average number of 
nucleotide differences
(k)
Average number of nucleotide 
substitutions per site
(Dxy)
Number of net nucleotide 
substitution between population
(Da)
Comparison at baseline
Malaria vaccine vs. control group 20.805 0.0172 0.0003
Pre- vs. post-immunization
Control group 20.694 0.0173 0.0004
Malaria vaccine group 20.773 0.0173 -0.0001
Comparison after immunization
Malaria vaccine vs. control group 20.739 0.0172 -0.00002
Comparisons with vaccine strains
At baseline
Controls vs. 3D7 19.971 0.0193 0.0111
Control group vs. FVO 19.775 0.0173 0.0091
Malaria vaccine group vs. 3D7 21.108 0.0166 0.0078
Malaria vaccine group vs. FVO 21.394 0.0193 0.0104
Post-immunization
Controls vs. 3D7 20.743 0.0179 0.0111
Control vs. FVO 20.768 0.0193 0.0107
Malaria vaccine group vs. 3D7 20.780 0.0176 0.009
Malaria vaccine group vs. FVO 20.807 0.0192 0.0106Ouattara et al. Malaria Journal 2010, 9:175
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and malaria vaccine group sequences after immunization
vs. control group sequences after immunization (p =
0.10).
Time to first malaria clinical episode with vaccine-type 
parasites
The time to disease with 3D7 and FVO c1L haplotype
was also measured. Individuals experienced their first
clinical episodes between 6 to 154 days post-immuniza-
t i o n  ( m e a n  7 9 . 2  d a y s ) .  S u r v i v a l  c u r v e s  ( F i g u r e  5 A ,  B )
showed no difference between the two groups in time to
clinical infection with a 3D7 or FVO c1L haplotype. The
occurrence of AMA1 3D7 type clinical episodes in the
two treatment arms was identical both at the beginning
(log rank test p-value = 0.88) and at the end of the follow
up period (Wilcoxon test p-value = 0.73). A similar obser-
vation was made when the strain under consideration
was FVO (Log rank p-value = 0.56 and Wilcoxon p-value
= 0.19).
A Cox proportional hazard regression was performed
to model the time to first malaria clinical episode with a
c1L haplotype exactly matching the 3D7 or FVO strain as
a function of study group. Hazard ratios obtained from
the model and vaccine allele-specific efficacy are shown
in Table 4. The hazard ratio for clinical illness caused by
parasites with 3D7-type AMA1 c1L was 1.06 with a 95%
confidence interval (CI) of 0.48-2.32. For FVO the hazard
ratio was 1.34 with 95% CI of 0.50-3.62. These results
support the conclusion that the AMA1 vaccine and con-
trol groups had similar risks of having clinical malaria
episodes with parasites similar to the vaccine strains with
respect to immunologically important polymorphic
amino acid residues.
Figure 3 Population structure of Plasmodium falciparum apical membrane antigen-1 (AMA1) sequences using DISTRUCT program [24]. The 
population structure of AMA1 was assessed using a Bayesian clustering method implemented in Structure 2.2 with k = 6. Each haplotype is represent-
ed by a vertical bar, and each color represents a population. Six populations are shown: Group 1 in red (3D7 group, haplotype 29), group 2 in green 
(FVO group, haplotype 49), group 3 in dark blue, group 4 in yellow, group 5 in pink and group 6 in light blue.Ouattara et al. Malaria Journal 2010, 9:175
http://www.malariajournal.com/content/9/1/175
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Discussion
The extensive genetic diversity that is maintained in
malaria vaccine candidate antigens through balancing
selection applied by host immunity may hamper the
development of effective malaria vaccines, especially
those targeting highly polymorphic blood stage antigens
such as AMA1 [35,28]. Molecular epidemiological stud-
ies can suggest which antigen variants might best be
included in vaccines based on their prevalence in natural
populations [16], and molecular epidemiological, popula-
tion genetics [30] and in vitro invasion inhibition studies
[19,36,37] all provide clues about which variants might
offer the most cross-protection in multivalent vaccine
formulations. However, only field trials of vaccine effi-
cacy against diverse parasites can provide definitive evi-
dence of cross-protection or the lack thereof. Here,
results are reported of analyses of allele-specific efficacy
of AMA1-C1, a bivalent AMA1 vaccine that was
designed to overcome allelic diversity in this extremely
polymorphic antigen by including two allelic variants of
the target antigen. AMA1-C1 is the first AMA1 vaccine
to be evaluated in a field trial measuring efficacy against
malaria in a natural setting.
The AMA1 sequences included in AMA1-C1 are
derived from the P. falciparum strains 3D7 and FVO.
These sequences were chosen based on the availability of
these two well-characterized culture-adapted strains with
divergent sequences, without knowledge of the baseline
distribution of the corresponding AMA haplotypes in the
natural parasite populations where the vaccine would be
tested and eventually deployed. The results of this study
show that, based on polymorphisms in the entire AMA1
ectodomain, fewer than 3% of AMA1 sequences exam-
ined from samples collected at the vaccine trial site had
haplotypes matching 3D7 while none had the FVO haplo-
types; very similar results were found at another vaccine
testing site in Mali [16]. Thus a possible explanation for
the failure of AMA1-C1 to demonstrate protection in a
Phase 2 trial in 300 Malian children was that allele-spe-
cific immune responses induced by the vaccine, even if
highly effective against parasites carrying homologous
forms of AMA1 (either with respect to the whole AMA1
Figure 4 Distribution of six Plasmodium falciparum apical membrane antigen-1 (AMA1) sequence groups before and after vaccination with 
the malaria vaccine and control vaccine. Group 1 (red) includes AMA1 sequence corresponding to the 3D7 vaccine strain of P. falciparum and Group 
2 (green) includes sequence corresponding to the FVO vaccine strain.
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Figure 5 Kaplan-Meier plot of survival curve without malaria clinical episode with a 3D7 or FVO c1L type allele following vaccination with 
apical membrane antigen-1 (AMA1) malaria vaccine or a control vaccine. Top panel, 3D7. Log rank statistic = 0.02, p = 0.88 and Wilcoxon statistic 
= 0.11 p = 0.73. Bottom panel, FVO. Log rank statistic = 0.35, p = 0.55 and Wilcoxon statistic = 1.70 p = 0.19.
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ectodomain or some subset of immunologically impor-
tant epitopes such as c1L on domain I), were not broadly
cross-protective enough to result in measurable efficacy
against parasitaemia [29]. If an insufficiently broad
immune response explained the lack of overall efficacy,
allele-specific vaccine-induced immune responses should
still have been directed against the fraction of parasites
with partial or full homology to 3D7 and FVO AMA1,
leading to a reduction in the frequency of these alleles fol-
lowing immunization.
The results of this study provide evidence that insuffi-
cient coverage of AMA1 diversity does not explain the
lack of vaccine efficacy. Several measures of genetic
diversity showed no impact of the vaccine on the diversity
of AMA1 alleles in infections experienced by vaccine
recipients compared to baseline or to infections in the
control group. Moreover, no significant association was
seen between vaccination and the risk of malaria clinical
episodes caused by parasites with AMA1 similar to the
vaccine strain with respect to immunologically dominant
regions of the AMA1 protein. There was a non-signifi-
cant ~1.6-fold lower incidence of clinical malaria caused
by parasites with AMA1 c1L haplotypes corresponding
to 3D7 following immunization with AMA1-C1 than
with a control vaccine (Table 4). However, this hint of
possible selection is at odds with the observation of
increases in the frequency of 3D7-type c1L in both treat-
ment groups during the post-immunization observation
period, and the lack of any suggestion of reduced risk of
clinical episodes caused by parasites with FVO-type
AMA1 c1L in the vaccine group.
It is more likely that AMA-C1 vaccine failed to protect
due to insufficient immunogenicity of the vaccine formu-
lation. For this reason, a new formulation of AMA1-C1
that includes the toll-like receptor agonist CPG 7909 has
been developed and tested in Phase 1 trials, which show
an approximately 12-14-fold increase in post-immuniza-
tion antibody levels compared to the formulation without
this additional adjuvant in malaria naïve populations, and
a 2.5-3-fold increase in antibody levels in malaria exposed
adults [38-40]. A monovalent AMA1 vaccine based on
the 3D7 strain and formulated with the AS02A adjuvant
system has also shown strong and sustained antibody
responses in Malian adults [41] and children [42]. Results
of a Phase 2 safety and efficacy study of this vaccine will
be available soon and may allow ascertainment of an
allele-specific effect of an AMA1 based malaria vaccine.
Limitations of this study include the possibility that
there was insufficient statistical power to detect a subtle
degree of allele-specific efficacy. P. falciparum infections
with AMA1 corresponding to the 3D7 strain with respect
to the entire ectodomain represented only 3% of all the
haplotypes present at the vaccine trial site at the start of
the study. Furthermore, only single or predominant
AMA1 sequences could be used to define haplotypes and
for population genetic analyses, also contributing to
reduced statistical power to detect differences between
the malaria vaccine and control groups. To detect a 50%
reduction in the frequency of full AMA1 haplotypes by
the vaccine, 1,534 unique or predominant AMA1
sequences would have been required to have 80% power
with significance at 5%. Statistical power is increased by
examining only haplotypes based on the eight polymor-
phic amino acid positions within the putatively immuno-
logically important region of AMA1, c1L of domain I--to
detect a similar effect, 586 unique or predominant c1L
haplotypes would be required, demonstrating the chal-
lenges of measuring allele-specific efficacy for vaccines
based on uncommon antigenic variants. However, the
conclusion that the vaccine had no effect on the distribu-
tion of AMA1 haplotypes is supported by the near-uni-
formity of several measures of genetic diversity and
divergence from the vaccine strains.
Conclusion
In this Phase 2 trial of the bivalent blood stage malaria
vaccine AMA1-C1 in Malian children, no evidence was
found of allele-specific efficacy. AMA1 sequences in
infections occurring in the vaccine and control groups
were remarkably similar before and after immunization
Table 4: Risk of malaria clinical episodes with an apical membrane antigen-1 (AMA1) cluster 1 loop (c1L) haplotype 
matching vaccine strains
Strain and vaccine group Hazard Ratio 95% confidence interval p-value
3D7 strain
Control vaccine Reference
AMA1-C1 1.06 0.48 - 2.32 0.89
FVO strain
Control vaccine Reference
AMA1-C1 1.34 0.50 - 3.62 0.57Ouattara et al. Malaria Journal 2010, 9:175
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Page 12 of 13
when examined using several complementary statistical
and population genetics methods. These results strongly
suggest that the AMA1-C1 vaccine failed not due to
inability to overcome extensive genetic diversity in
AMA1, but for another reason, most likely an insuffi-
ciently immunogenic vaccine formulation. Two second
generation AMA1 vaccines with more immunogenic
adjuvant systems are being evaluated in field trials in
Mali. Results of these trials should provide evidence on
which to base decisions about whether or not further
development of AMA1-based vaccines is warranted, and
to guide optimal choices of AMA1 haplotypes to include
in a multivalent AMA1 malaria vaccine.
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